Critical Survey: Pfizer (PFE) versus The Competition

Pfizer (NYSE:PFE – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Pfizer to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings.

Earnings and Valuation

This table compares Pfizer and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pfizer $62.58 billion $7.77 billion 41.20
Pfizer Competitors $3.55 billion $3.17 billion 559.01

Pfizer has higher revenue and earnings than its rivals. Pfizer is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

68.4% of Pfizer shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pfizer 6.34% 19.88% 8.52%
Pfizer Competitors -2,400.61% -215.91% -15.58%

Analyst Ratings

This is a breakdown of current ratings and price targets for Pfizer and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer 2 14 6 0 2.18
Pfizer Competitors 7845 13798 25820 1039 2.41

Pfizer presently has a consensus price target of $30.32, indicating a potential upside of 5.12%. As a group, “Pharmaceuticals” companies have a potential upside of 24.61%. Given Pfizer’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Pfizer has less favorable growth aspects than its rivals.

Dividends

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.0%. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years.

Volatility and Risk

Pfizer has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Pfizer’s rivals have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.

Summary

Pfizer beats its rivals on 8 of the 15 factors compared.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.